Table 1

Clinical outcome of the primary chemoprevention trial in FAP

Polyp development*Total n = 41Sulindac group n = 21Placebo group n = 20
Yes (non-responders)20 (49)9 (43)11 (55)
No (responders)21 (51)12 (57)9 (45)
  • NOTE. Values are expressed as number (%).

  • * The outcome of the trial was assessed by whether patients developed polyps as determined by examination of the rectum with a flexible sigmoidoscope at the end of the 4-year trial.